West Pharmaceutical Services, Inc. - 10-Q Summary (Q2 2004)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2004, for West Pharmaceutical Services, Inc., a manufacturer of pharmaceutical closure systems and drug delivery technologies. The company operates primarily through two segments: Pharmaceutical Systems and Drug Delivery Systems. The reporting period reflects ongoing operational adjustments following a 2003 plant explosion in Kinston, North Carolina.
Key Financial Metrics
| Metric (in thousands) | Q2 2004 | Q2 2003 | YTD 2004 | YTD 2003 |
|---|---|---|---|---|
| Net Sales | $138,100 | $126,400 | $271,700 | $244,200 |
| Gross Profit | $42,800 | $41,400 | $83,400 | $77,800 |
| Operating Profit | $11,600 | $10,800 | $22,400 | $17,300 |
| Net Income | $7,700 | $6,900 | $14,700 | $10,700 |
| Diluted EPS | $0.50 | $0.48 | $0.96 | $0.74 |
| Cash from Operations (YTD) | $26,800 (2004) vs $25,700 (2003) | |||
| Total Debt (Long-term + Notes) | $158,000 (June 30, 2004) | |||
| Cash & Equivalents | $52,900 (June 30, 2004) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9% in Q2 and 11% year-to-date compared to 2003. Growth was driven by the Pharmaceutical Systems segment (9% Q2 increase), with 3% of the Q2 increase attributed to foreign currency translation.
- Profitability: Net income rose 12% in Q2 and 38% year-to-date. This improvement occurred despite ongoing costs related to the Kinston plant explosion.
- Kinston Impact: In Q2 2004, the company incurred $3.1 million in additional production and business interruption costs due to interim production procedures following the 2003 explosion. Unlike 2003, no insurance recoveries offset these costs in 2004 as the final settlement was recorded in late 2003.
- Corporate Expenses: Corporate costs increased to $7.4 million in Q2 2004 from $5.1 million in 2003, largely due to a $1.8 million expense from a new performance vesting restricted stock plan and compliance costs (Sarbanes-Oxley/FDA).
- Segment Performance: The Drug Delivery Systems segment reported an operating loss of $4.2 million in Q2 2004, an increase from the $3.7 million loss in Q2 2003, driven by spending on clinical development programs.
Guidance, Outlook, and Risks
- Strategic Review: In June 2004, the company announced plans to explore strategic alternatives for its Drug Delivery Systems segment.
- Capital Expenditures: Full-year 2004 capital spending is projected at approximately $60 million, including $14 million for the replacement of the Kinston facility, expected to be fully operational by year-end.
- Debt Covenants: The company replaced its revolving credit facility in May 2004 with a $125 million commitment. As of June 30, 2004, the Leverage Ratio was 28.4% (limit 50%) and Consolidated Net Worth was $255.2 million (minimum $198.9 million).
- Risks: Key risks include the timely replacement of Kinston production capacity, the adequacy of insurance recoveries for liability claims, and the impact of a change in Danish tax law on the effective tax rate. The company is also a defendant in a lawsuit regarding the Kinston explosion, though it believes insurance is sufficient to cover expected losses.
- Dividends: A quarterly dividend of $0.21 per share was declared on June 29, 2004.
Investor Verification Checklist
- Verify the timeline and budget adherence for the new Kinston compression molding facility to ensure production capacity is restored as projected.
- Monitor the status of the lawsuit regarding the Kinston explosion and any potential uninsured liability costs.
- Review the progress of the strategic alternatives review for the Drug Delivery Systems segment.
- Assess the impact of the new performance-based stock compensation plan on future earnings volatility.
- Track the effective tax rate, specifically regarding the impact of the Danish tax law change mentioned in management commentary.